Check out my new post!

Croda has not said Zenakine will be made at its new Guangzhou facility. But its FY25 language around a China-based F&F and Actives site, combined with Zenakine’s apparent IECIC pathway and Croda’s broader “Made in China for China” push, makes the read-through hard to ignore.

The real significance is not simply local production. It is whether Zenakine can become a credible China-facing beauty active in one of the world’s largest skincare markets. With regulatory usability, a fashionable neurocosmetic positioning, and supporting scientific and clinical data behind its stress, sleep and skin-regeneration claims, Zenakine has more than the usual ingredient-industry pixie dust.

The caveat is equally important: there is no official confirmation of Chinese manufacture, no disclosed material sales traction, and no proof yet of major brand adoption. For now, Guangzhou looks less like a smoking gun than a commercial accelerant — potentially powerful, but still awaiting ignition.

• Croda Zenakine

• Zenakine China

• Croda Guangzhou facility

• Croda Beauty Actives China

• Croda FY25 results

• Croda Made in China for China

• Zenakine IECIC

• Lactobacillus Ferment Lysate IECIC

• China cosmetic ingredients

• IECIC List I

• NMPA cosmetic ingredients

• China skincare market

• China beauty ingredients market

• neurocosmetics

• neurocosmetic active ingredient

• stress ageing skincare

• sleep beauty skincare

• melatonin skincare

• postbiotic skincare active

• biotech beauty ingredients

• Croda beauty ingredients

• premium skincare actives

• China cosmetics regulation

• Chinese skincare brands

• cosmetic claims substantiation

• active ingredients China

• beauty actives market

• skin regeneration ingredient

• Lactobacillus Ferment Lysate

• Croda investor analysis